Evaluation of Plasma Levels of Thymidine Kinase and Mutated P53 in 81 Patients with Newly Diagnosed Malignant Lymphoma

Authors

  • Tuula Lehtinen Department of Clinical Oncology and Pathology, Tampere University Central Hospital and Institutes of Biomedical and Clinical Sciences, University of Tampere, Tampere, Finland
  • Risto Aine Department of Clinical Oncology and Pathology, Tampere University Central Hospital and Institutes of Biomedical and Clinical Sciences, University of Tampere, Tampere, Finland
  • Pirkko Kellokumpu-Lehtinen Department of Clinical Oncology and Pathology, Tampere University Central Hospital and Institutes of Biomedical and Clinical Sciences, University of Tampere, Tampere, Finland
  • Tapani Hakala Department of Clinical Oncology and Pathology, Tampere University Central Hospital and Institutes of Biomedical and Clinical Sciences, University of Tampere, Tampere, Finland
  • Matti Lehtinen Department of Clinical Oncology and Pathology, Tampere University Central Hospital and Institutes of Biomedical and Clinical Sciences, University of Tampere, Tampere, Finland

DOI:

https://doi.org/10.3109/02841869309096135

Abstract

We analysed diagnostic phase plasma levels of thymidine kinase (TK) and mutated p53 in 81 patients with malignant lymphoma. Forty-three (53%) patients had increased (> 10 U/1) TK activity whereas 30 (37%) were positive for the mutated p53 gene product. In general, patients with p53 mutation positive tumors tended to have higher TK activity than those without. Furthermore, patients with high-grade non-Hodgkin's lymphoma (NHL) showed almost a linear correlation (rs = 0.79) between plasma levels of mutated p53 and TK. We conclude that the monoclonal antibody assisted detection of mutated p53 gene product may prove a useful adjunct to the diagnostic procedures of malignant lymphomas.

Downloads

Download data is not yet available.

Downloads

Published

1993-01-01

How to Cite

Lehtinen, T. ., Aine, R. ., Kellokumpu-Lehtinen, P. ., Hakala, T. ., & Lehtinen, M. . (1993). Evaluation of Plasma Levels of Thymidine Kinase and Mutated P53 in 81 Patients with Newly Diagnosed Malignant Lymphoma. Acta Oncologica, 32(7-8), 779–781. https://doi.org/10.3109/02841869309096135

Issue

Vol. 32 No. 7-8 (1993): Acta Oncologica

Section

Articles